Tagalakis et al. developed lipid-based and polymer-based nanoparticles to deliver siRNA targeting MYCN intravenously, effectively inhibiting the growth of neuroblastoma xenografts and prolonging the survival of mice (Tagalakis et al., 2021). This evidence concerns the gene MYCN and neuroblastoma.